Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML) [0.03%]
急性髓系白血病(AML)临床I期试验的新型BET溴结构域蛋白抑制剂研究
Thorsten Braun,Claude Gardin
Thorsten Braun
Acute myelogenous leukemia (AML) is a heterogeneous group of malignancies driven by genetic mutations and deregulated epigenetic control. Relapse/refractory disease remains frequent in younger patients and even more so in older patients, in...
Investigational drugs in phase I and phase II clinical trials for thalassemia [0.03%]
地中海贫血一期和二期临床试验的 investigational drugs
Irene Motta,Natalia Scaramellini,Maria Domenica Cappellini
Irene Motta
Regular transfusion and iron chelation are the current treatment of severe forms of thalassemia. As a consequence of this demanding supportive treatment, there are several unmet therapeutic needs. Due to a deeper understanding in the pathop...
Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias [0.03%]
左旋多巴诱发不自主运动的I期和II期研究药物
Silvia Cerri,Francesca Siani,Fabio Blandini
Silvia Cerri
Prolonged treatment of Parkinson's disease (PD) with levodopa (L-DOPA) results in motor complications, including motor fluctuations and involuntary movements known as L-DOPA induced dyskinesias (LIDs). LIDs represent an additional cause of ...
Vincent Soriano,Pablo Barreiro,Laura Benitez et al.
Vincent Soriano et al.
Current treatment with oral nucleos(t)ides entecavir or tenofovir provide sustained suppression of HBV replication and clinical benefit in most chronic hepatitis B virus (HBV) infected persons. However, HBV rebound generally occurs upon dru...
Jesus Egido,Jorge Rojas-Rivera,Sebastian Mas et al.
Jesus Egido et al.
Endothelin-1 (ET-1) is the most potent vasoconstrictor, and is involved in the renal regulation of salt and water homeostasis. When produced in excess in the kidney, ET-1 promotes proteinuria and tubulointerstitial injury. There is great in...
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer [0.03%]
间变性淋巴瘤激酶抑制剂在非小细胞肺癌I期和II期临床试验中的研究进展
Niki Karachaliou,Mariacarmela Santarpia,Maria Gonzalez Cao et al.
Niki Karachaliou et al.
Crizotinib is a first-in-class ALK tyrosine kinase inhibitor (TKI), which has proven its superiority over standard platinum-based chemotherapy for the first-line therapy of ALK-rearranged non-small cell lung cancer (NSCLC) patients. The dev...
The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects [0.03%]
神经生成药物NSI-189磷酸盐：一种新型多领域治疗方法，能够产生促认知和抗抑郁作用
Roger S McIntyre,Karl Johe,Carola Rong et al.
Roger S McIntyre et al.
Alterations in neurogenic and neurotrophic processes as well as intracellular signalling cascades provides the basis for hypothesizing that neurogenic agents may be therapeutic across multiple RDoC-defined domains (e.g. positive valence sys...
Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015 [0.03%]
2010至2015年阿尔茨海默病药物研发失利的再思考
Dev Mehta,Robert Jackson,Gaurav Paul et al.
Dev Mehta et al.
There are dozens of drugs in development for AD with billions of dollars invested. Despite the massive investment in AD drugs and a burgeoning pipeline, there have been more setbacks and failures than treatment successes. Areas covered: The...
Drugs in preclinical to phase II clinical development for the treatment of erectile dysfunction [0.03%]
处于临床前至II期临床开发用于治疗勃起功能障碍的药物
Li Smith-Harrison,Nathan R Starke,Ryan P Smith et al.
Li Smith-Harrison et al.
Erectile function is an important aspect in the quality of life of many men. For men with erectile dysfunction (ED), a spectrum of treatment options exists. Novel therapies for ED are currently being developed in order to delay surgical pla...
Mattia D&#x;Agostino,Marco Salvini,Antonio Palumbo et al.
Mattia D&#x;Agostino et al.
Multiple myeloma (MM) is a hematologic malignancy characterized by proliferation of malignant plasma cells. patient outcome has improved markedly over the last decades due to the introduction of novel therapeutic agents such as bortezomib, ...